Transgene Biotek, a relatively small pharma company from Andhra Pradesh, has commenced the construction work of an additional FDA compliant facility for the manufacture of newly developed APIs products. The company raised US$ 23 million through GDR during February 2011 and now decided to undertake a restructuring exercise to provide impetus to the rapidly advancing R&D pipeline and the burgeoning API division. It is also looking at inorganic growth to boost its revenues and capabilities.
The company has began to generate revenues in its API division from sales of the newly developed immuno-suppressive drug Tacrolimus, and the nutraceutical Omega-3 fatty acid DHA. Its four molecules reached the final stage of pre-clinical development. With this success, the management has decided to restructured the R&D division along clinical application lines such as oncology drugs, auto-immune drugs, and oral delivery of protein drugs so as to provide specific focus to each area.